liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study
Karolinska University Hospital, Sweden; Karolinska Institute, Sweden.
Karolinska University Hospital, Sweden; Karolinska Institute, Sweden.
Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Haematology.
Kristianstad Central Hospital, Sweden.
Show others and affiliations
2015 (English)In: Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, ISSN 0145-2126, E-ISSN 1873-5835, Vol. 39, no 1, 33-37 p.Article in journal (Refereed) Published
Abstract [en]

There have been concerns about serious infusion-related adverse drug reactions (ADR) with rituximabin chronic lymphocytic leukemia (CLL). We therefore conducted an observational trial in which CLL patients planned for rituximab-containing therapy were eligible. Ninety-six patients from 19 centers were enrolled. The most common regimen was rituximab, fludarabine and cyclophosphamide. Fifty-six patients experienced ADR during rituximab infusion. Reactions greater than= grade 3 occurred in five patients and no cases of tumor lysis syndrome were recorded. Despite a high number of circulating tumor cells few severe ADR were noted. Thus, rituximab containing regimens can be considered safe for CLL patients in general practice.

Place, publisher, year, edition, pages
Elsevier , 2015. Vol. 39, no 1, 33-37 p.
Keyword [en]
Adverse reaction; Chronic lymphocytic leukemia; Rituximab; Therapy
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-114250DOI: 10.1016/j.leukres.2014.09.019ISI: 000346858200005PubMedID: 25499233OAI: oai:DiVA.org:liu-114250DiVA: diva2:788637
Note

Funding Agencies|Roche Sweden AB [ML22754]

Available from: 2015-02-16 Created: 2015-02-16 Last updated: 2017-12-04

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Haematology
In the same journal
Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 38 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf